What is HC Wainwright's Estimate for ARTV FY2024 Earnings?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($6.00) per share for the year. HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.68) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.92) EPS.

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of "Buy" and an average target price of $21.00.

Artiva Biotherapeutics Stock Down 4.7 %

Artiva Biotherapeutics stock traded down $0.50 during trading hours on Wednesday, hitting $10.08. The company had a trading volume of 66,072 shares, compared to its average volume of 117,256. The business's 50-day moving average is $11.37. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of ARTV. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $42,000. MetLife Investment Management LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter worth $135,000. JPMorgan Chase & Co. acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at $166,000. Barclays PLC bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $304,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth $623,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.